Article

Diagnosis and Management of Adnexal Masses

Department of Family Medicine, University of Tennessee Health Science Center College of Medicine, Memphis, TN 38119 , USA.
American family physician (Impact Factor: 2.18). 10/2009; 80(8):815-20.
Source: PubMed

ABSTRACT

Adnexal masses represent a spectrum of conditions from gynecologic and nongynecologic sources. They may be benign or malignant. The initial detection and evaluation of an adnexal mass requires a high index of suspicion, a thorough history and physical examination, and careful attention to subtle historical clues. Timely, appropriate laboratory and radiographic studies are required. The most common symptoms reported by women with ovarian cancer are pelvic or abdominal pain; increased abdominal size; bloating; urinary urgency, frequency, or incontinence; early satiety; difficulty eating; and weight loss. These vague symptoms are present for months in up to 93 percent of patients with ovarian cancer. Any of these symptoms occurring daily for more than two weeks, or with failure to respond to appropriate therapy warrant further evaluation. Transvaginal ultrasonography remains the standard for evaluation of adnexal masses. Findings suggestive of malignancy in an adnexal mass include a solid component, thick septations (greater than 2 to 3 mm), bilaterality, Doppler flow to the solid component of the mass, and presence of ascites. Family physicians can manage many nonmalignant adnexal masses; however, prepubescent girls and postmenopausal women with an adnexal mass should be referred to a gynecologist or gynecologic oncologist for further treatment. All women, regardless of menopausal status, should be referred if they have evidence of metastatic disease, ascites, a complex mass, an adnexal mass greater than 10 cm, or any mass that persists longer than 12 weeks.

Download full-text

Full-text

Available from: Vanessa m Givens
  • Source
    • "This biomarker is particularly accurate among postmenopausal women, in whom the positive predictive value (PPV) reaches 98%, compared with only 49% in premenopausal patients [8]. However, CA-125 is nonspecific and can be elevated under many other conditions, including benign gynecologic etiologies, nongynecologic diseases, and other malignancies, such as breast or endometrial cancers [9] [10]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To evaluate the clinical significance of the combination of cancer antigen-125 (CA-125), human epididymis protein 4 (HE4), and progesterone for the identification of ovarian masses in patients with suspected early stage ovarian cancer (OC). Materials and methods: This was a case-control, single-center study of 225 women with a pelvic mass of suspected ovarian origin, including 75 patients with Stage I/II OC and 150 controls. Diagnostic procedures included pelvic and rectal examinations, transvaginal ultrasound, evaluation of CA-125 and HE4 levels alone and in the Risk of Ovarian Malignancy Algorithm (ROMA), and a new algorithm combining ROMA and progesterone. Results: Median CA-125 and HE4 levels were significantly higher in patients with OC compared with women with benign ovarian tumors, irrespective of menopausal status. The highest median progesterone levels occurred in premenopausal women with benign ovarian tumors, compared with premenopausal women with OC with or without benign ovarian disease. The combination of ROMA and progesterone was significantly more accurate at detecting OC compared with ROMA or CA-125 or HE4 alone, but only in premenopausal patients. Conclusion: Different algorithms should be used for diagnosing OC, and the addition of progesterone might improve the performance of ROMA for the diagnosis of pelvic masses in premenopausal women.
    Full-text · Article · Dec 2015 · Taiwanese Journal of Obstetrics and Gynecology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cell-free circulating DNA carries not only tumor-specific changes in its sequence but also distinctive epigenetic marks, namely DNA methylation, in certain GC-rich fragments. These fragments are usually located within the promoters and first exons of many genes, comprising CpG islands. Analysis of DNA methylation using cell-free circulating DNA can facilitate development of very accurate biomarkers for detection, diagnosis, prediction of response to therapy and prognosis of outcomes. Recent data suggest that benign and inflammatory diseases have very specific methylation patterns within cell-free circulating DNA, which are different from the pattern of a malignant tumor of the same organ. In addition, specific methylation patterns have been detected for cancers of different organs, so a differential diagnosis of site-specific cancer appears feasible. Currently, cancer-related applications dominate the field, although methylation-based biomarkers may also be possible for other diseases, including neurodegenerative and psychiatric disorders.
    Full-text · Article · May 2010 · Expert Review of Molecular Diagnostics
  • [Show abstract] [Hide abstract]
    ABSTRACT: We aimed to evaluate and compare the management and clinical characteristics of adnexal masses in postmenopausal and reproductive age women. This prospective study was performed at Dicle University, School of Medicine, Department of Obstetrics and Gynecology, from January 2007 to June 2009.The data were collected from hospital records and patients files, descriptively. The cases were divided into two groups as cases with adnexal masses in postmenopausal age women (Group 1, n = 40), and reproductive age (Group 2, n = 40). All of the cases operated for benign adnexal masses. Statistical analyses were carried out by using the statistical packages for SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA). The demographic characteristics of the cases that were enrolled in our study are depicted in Table 1.The initial compliant of the cases were abdominal pain in 62 (77.5%) of the cases and 8 (20%) vaginal bleeding and 10 (12.5%) were asymptomatic. The initial diagnose of the cases were; pelvic mass in 34 (75%) of the cases, ovarian cyst 26 (32.5%), dermoid cyst 10 (12.5%), endometrioma 7 (8.75%) and postmenopausal bleeding 4 (5%). The tumor markers were evaluated. All of the cases were subjected to laparotomy or laparoscopy. The frozen section diagnose were made by the pathology department. The postoperative characteristics of the masses were also evaluated. The adnexal masses in postmenopausal woman with benign characteristics can be followed conservatively, without surgery. Surgery may be indicated to women with family history of cancer, a mass that appears enlarging and symptomatic.
    No preview · Article · Jan 2011 · Journal of Experimental Therapeutics and Oncology
Show more